Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Double-blind, Randomized, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Effectiveness of AA4500 In the Treatment of Dupuytren's Disease Nodules

Next Previous
Trial Profile

A Phase 2a, Double-blind, Randomized, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Effectiveness of AA4500 In the Treatment of Dupuytren's Disease Nodules

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 30 Sep 2016 Primary endpoint has been met. (Percent Change From Baseline in Surface Area and Volume of the Treated Nodule at Day 57 Using Caliper Measurements), as reported in an Endo Pharmaceuticals media release.
  • 30 Sep 2016 According to an Endo Pharmaceuticals media release, new data evaluating the safety and efficacy of Collagenase-clostridium-histolyticum injection will be presented during a podium presentation at the annual meeting of the American Society for Surgery of the Hand (ASSH) 2016.
  • 30 Sep 2016 Results published in an Endo Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top